August Newsletter
Hi, neurotech enthusiasts from NYC and beyond👋
Who are we? We are NeuroNYC, and our mission is to cultivate the neurotech community within the NYC area. We bring together founders, researchers, clinicians, investors, operators, artists, and policymakers across the entire neurotech ecosystem, spanning BCIs, neuromodulation, digital health, AI-driven neuroscience, and more.
Our goal is simple: build a high-signal, human-scale community that helps neurotech move from the lab to real-world impact.
🌷 Recap:
Thank you to everyone who joined our 2nd Annual NeuroNYC Neurotech Summit, where we unveiled the State of Neurotech in Greater NY (2025–2026) report. The big picture: 2025–2026 marked a translation inflection point, with NY’s academic institutions specializing in specific topics rather than competing. Capital told a barbelled story (a few large rounds atop many sub-$5M deals, with only 13 of 48 regional funders doing dedicated neuro underwriting), and the durable moat is shifting from any single sensor toward “device + data + workflow.“ The ecosystem’s biggest gaps are translational, not scientific, which is why 2027–2030 shapes up as a readout period, where the current pipeline either crosses into repeatable care and scalable businesses, or doesn’t.
We also stayed busy with our NeuroNYC GP/LP Happy Hour, a curated evening for investors across neurotech, mental health, brain health, and neurodegenerative disease (Emerging Managers included), and partnered on the NYC Neuromodulation Conference(Congratulations to our advisor Dr. Marom Bikson and the City College of New York team on the great success!), where we hosted a student social hour and a Women in Neurotech event. Great to bring both the investor community and the next generation of researchers together.
🗓️ Events:
NeuroNYC x Precision Neuroscience Event, September 10th: Are you a student or an early-career professional looking to break into the neurotech industry? Save the date for an evening on building your career in brain-computer interfaces with Joel Greengrass, Chief People Officer at Precision Neuroscience. Keep an eye out for more details on our LinkedIn.
Mental Health Build, September 25th: Are you an engineer, MBA student, or rising professional looking to break into mental or brain health, or a company hunting for your next great hire? Then this one’s for you. GreyMatter has teamed up with Julia Bernstein’s #HiringFriday to connect the sharpest builders in the space with the talent to help them grow. Two ways to take part:
Talent (apply by September 7th): Engineers, MBA students, and rising professionals can apply (click) to attend and find their next opportunity in the space.
Companies (apply by August 14th): Teams building in mental health, health tech, or neurotech can apply (click) to meet their next great hire.
Check out our LinkedIn to stay updated: https://www.linkedin.com/company/neuronyc
Looking further ahead:
New York Brain-Computer Interface Symposium, November 5th & 6th: Join Mount Sinai BioDesign for NYBCI, a global symposium returning to New York City for two days of bold keynotes, panels, and breakout sessions led by the world’s foremost experts in neuroscience, surgery, neurotech, and regulation in the brain-computer interface world. Register here.
🧠 NeuroNYC News:
📣 NeuroNYC is looking for a volunteer! Are you passionate about social media strategy, content, and community engagement? We’re looking for someone to manage and grow our Instagram and LinkedIn presence. 📩 Email us: hello@neuro-nyc.org
🗽 Neurotech News in NYC:
Sero Labs: Our very own Saar Lively, president/co-founder of NeuroNYC, has launched Sero Labs, a Brooklyn-based non-invasive neurotechnology company applying the science of human connection.
Sharper Sense: Sharper Sense, founded by NeuroNYC chair/co-founder Charlie Rodenkirch, was awarded an Empire State Development (NYSTAR) Innovation Matching Grant to support commercialization.
Precision Neuroscience: Precision Neuroscience appointed John Donoghue, a pioneer of brain-computer interfaces, as Scientific Advisor.
Feinstein Institutes (Northwell): Spark Biomedical and the Feinstein Institutes published a first-in-human study showing their non-invasive tAN technology enhances platelet function.
🔎 For the curious souls who want to read more neurotech newsletters:
For those curious about keeping up with the fast-advancing neurotechnology landscape, Neurotech Notables by Naveen Rao is the biweekly newsletter covering everything moving in neurotech, including funding, breakthroughs, industry shifts, and the deals you’ll be hearing about next:
Chay Carter and Max Kelly have co-founded Reccy Neuro, a platform providing personalized recruiting for neurotech jobs. Check out their newsletter:
Want something in the next newsletter? Send it my way: fay4004@med.cornell.edu
Until next time,
Fargol Yeganeh Fathi
Head of Academic Partnerships @ NeuroNYC